FMS-like tyrosine kinase 3 (Internal Tandem Duplication) gene mutation in Acute Myeloid Leukemia patients and its association with CD34
mohamed elprince, R., Ahmad, E., Abdel-motty, A., Haggag, R. (2022). FMS-like tyrosine kinase 3 (Internal Tandem Duplication) gene mutation in Acute Myeloid Leukemia patients and its association with CD34. EKB Journal Management System, 28(6.1), 309-315. doi: 10.21608/zumj.2020.23639.1726
reem alaa eldeen mohamed elprince; Ebtesam ebrahim Ahmad; Alaa Abdel-motty; Rasha Haggag. "FMS-like tyrosine kinase 3 (Internal Tandem Duplication) gene mutation in Acute Myeloid Leukemia patients and its association with CD34". EKB Journal Management System, 28, 6.1, 2022, 309-315. doi: 10.21608/zumj.2020.23639.1726
mohamed elprince, R., Ahmad, E., Abdel-motty, A., Haggag, R. (2022). 'FMS-like tyrosine kinase 3 (Internal Tandem Duplication) gene mutation in Acute Myeloid Leukemia patients and its association with CD34', EKB Journal Management System, 28(6.1), pp. 309-315. doi: 10.21608/zumj.2020.23639.1726
mohamed elprince, R., Ahmad, E., Abdel-motty, A., Haggag, R. FMS-like tyrosine kinase 3 (Internal Tandem Duplication) gene mutation in Acute Myeloid Leukemia patients and its association with CD34. EKB Journal Management System, 2022; 28(6.1): 309-315. doi: 10.21608/zumj.2020.23639.1726

FMS-like tyrosine kinase 3 (Internal Tandem Duplication) gene mutation in Acute Myeloid Leukemia patients and its association with CD34

Zagazig University Medical Journal
Article 43, Volume 28, Issue 6.1, November 2022, Page 309-315  XML PDF (307.05 K)
Document Type: Original Article
DOI: 10.21608/zumj.2020.23639.1726
View on SCiNiTO View on SCiNiTO
Authors
reem alaa eldeen mohamed elprince email 1; Ebtesam ebrahim Ahmad2; Alaa Abdel-mottyorcid 3; Rasha Haggagorcid 4
1clinical pathology, faculty of medicine, zagazig university, el sharkeya, egypt
2clinical pathology, faculty of medicine ZAG.university
3Faculty of Medicine, Zagazig University, Department of Clinical Pathology, Sharkia Egypt
4medical oncology department, faculty of medicine, zagazig university, sharkia, egypt
Abstract
Background: Acute myeloid leukemia (AML) is a heterogeneous disorder characterized by clonal expansion of myeloid progenitors in the bone marrow and peripheral blood Objectives: This study aimed to assess the role of FLT3 (ITD) gene mutation in AML patients and to find out the impact of the CD34 expression in these cases. Subjects : 30 subjects of adult patients with newly diagnosed AML were included in this study. Results: Patients were classified into favorable (6.6%), intermediate (80%) and unfavorable (13.3%) according to cytogenetic abnormalities. Mean value of CD34% (± SD) among cases was 45.53±25.32 with median 35.85 and range (5-91), While it was 42.52±29.9 with median 30.85 and range (5-91) among FLT3-ITD positive cases and 44.21±22.67 with median 39.3and range (16-88) among FLT3-ITD negative cases with no significant statistical relation between FLT3-ITD gene and CD34, P (0.672). CD34 positivity among FLT3-ITD positive cases showed 9 cases (75%) CD34% positive and 3 cases (25%) CD34% negative while among FLT3-ITD negative cases there were 15 cases (83.3%) CD34% positive and 3 cases (16.7%) CD34% negative, with no significant statistical relation. As regard the outcome, among FLT3-ITD positive cases 5 cases (41.7%) underwent relapse and 7 cases (58.3%) died. On the other hand among FLT3-ITD negative cases one case (5.6%) underwent relapse and 11 cases (61.1%) died, There is significant elevation in the relapsed cases among the FLT3-ITD positive cases (P = 0.025), while there is no significant relation between FLT3-ITD gene and death with (P = 0.879).
Keywords
Adoptive cell therapy; Acute myeloid leukemia; Adenosine tri phosphate
Statistics
Article View: 207
PDF Download: 67